Apollon Wealth Management LLC Lowers Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Apollon Wealth Management LLC has reduced its stake in Thermo Fisher Scientific by 35.7%, lowering its holdings to 12,153 shares after selling 6,743 shares during the second quarter.
• Multiple large investors, including Nuveen LLC and EdgePoint Investment Group Inc., have recently either increased or established new stakes in Thermo Fisher Scientific, indicating strong institutional interest in the company.
• Analysts maintain a consensus rating of "Moderate Buy" for Thermo Fisher Scientific, with an average price target of $593.43, suggesting potential upside for investors.

Apollon Wealth Management LLC lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 35.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 12,153 shares of the medical research company's stock after selling 6,743 shares during the quarter. Apollon Wealth Management LLC's holdings in Thermo Fisher Scientific were worth $4,928,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in TMO. Nuveen LLC purchased a new position in Thermo Fisher Scientific during the first quarter valued at approximately $532,360,000. EdgePoint Investment Group Inc. purchased a new position in shares of Thermo Fisher Scientific in the first quarter worth $172,139,000. Cohen Investment Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 6,655.5% in the first quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock worth $167,271,000 after buying an additional 331,180 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Thermo Fisher Scientific by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after buying an additional 329,974 shares in the last quarter. Finally, Auto Owners Insurance Co lifted its holdings in shares of Thermo Fisher Scientific by 6,773.5% in the first quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company's stock worth $143,309,000 after buying an additional 283,810 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TMO shares. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. William Blair assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research report on Thursday. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research report on Saturday, September 27th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average price target of $593.43.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Marc N. Casper sold 400 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the sale, the chief executive officer directly owned 113,762 shares of the company's stock, valued at $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 1.8%

TMO stock opened at $524.95 on Friday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The stock has a market capitalization of $198.23 billion, a price-to-earnings ratio of 30.36, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. The firm's fifty day simple moving average is $488.68 and its two-hundred day simple moving average is $447.94.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same quarter in the previous year, the business posted $5.37 earnings per share. The business's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.